SUPN - Supernus Pharmaceuticals GAAP EPS of $0.04 misses by $0.20 revenue of $159.05M in-line
Supernus Pharmaceuticals press release (NASDAQ:SUPN): Q4 GAAP EPS of $0.04 misses by $0.20. Revenue of $159.05M (+10.8% Y/Y) in-line. 2022 Guidance: Total revenues $640 - $680M, Combined R&D and SG&A expenses $460 - $490M, Operating earnings $20 - $40M, Effective tax rate 25% - 28%. Shares -1.69%.
For further details see:
Supernus Pharmaceuticals GAAP EPS of $0.04 misses by $0.20, revenue of $159.05M in-line